TOPADUR Pharma AG is a clinical-stage swiss biopharmaceutical start-up based in Schlieren, Zurich.
We strive for significant improvement of patients’ quality of life while providing sustainable high growth value for investors and employees.
The company has discovered the DualTOP™ technology platform consisting of new dual-acting drugs.
We developed an attractive portfolio of drug candidates to address high unmet needs in aging diseases.
Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, age-related macula degeneration, diabetic retinopathy, colorectal cancer, hair loss and skin aging.
TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.
EMA grants TOP-N53 Orphan Drug Designation for the Treatment of Digital Ulcers in Systemic Sclerosis.Read more
TOPADUR Pharma AG announces positive results from a First-in-Human study evaluating the safety, tolerability and efficacy of TOP-N53.Read more
TOPADUR announces the completion of Phase 1 dose escalation study of TOP-N53, a first-in-class wound healing drug candidate.Read more